Actively Recruiting
INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)
Led by Beijing Tiantan Hospital · Updated on 2026-03-16
2500
Participants Needed
1
Research Sites
69 weeks
Total Duration
On this page
Sponsors
B
Beijing Tiantan Hospital
Lead Sponsor
R
RenJi Hospital
Collaborating Sponsor
AI-Summary
What this Trial Is About
This project aims to evaluate the safety and efficacy of the antiplatelet regimen combining indobufen and clopidogrel in preventing ischemic events after stent-assisted coiling embolization and flow diverter implantation for intracranial aneurysms. Using a randomization system, patients with unruptured intracranial aneurysms scheduled for interventional treatment will be divided into an experimental group and a control group. Patients in the experimental group will be required to take indobufen (100 mg twice daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. Patients in the control group will be required to take aspirin (100 mg once daily) + clopidogrel (75 mg once daily) starting 5 days before the procedure and continuing until 180 days postoperatively. An independent group of researchers will assess cerebrovascular thromboembolic events and bleeding events at different time points.
CONDITIONS
Official Title
INdobufen Versus asPirin in Endovascular Unruptured Intracranial Aneurysms Treatment (INPUT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 to 75 years, male or female
- Radiologically confirmed saccular intracranial aneurysm
- Scheduled for endovascular embolization including coil embolization with stent assistance or flow diversion
- Signed informed consent obtained
You will not qualify if you...
- Presence of other brain diseases such as vascular malformations, tumors, abscesses, or multiple sclerosis
- Major surgery within 30 days before enrollment including fracture surgery or hip replacement
- History of ischemic stroke, ischemic heart disease, or bleeding disorders including intracranial hemorrhage, gastrointestinal bleeding, fundus hemorrhage, or unexplained bleeding within past 6 months
- Planned elective surgery within 3 months after the procedure
- Hematologic disorders or inherited coagulation abnormalities
- Severe kidney or liver dysfunction
- History of bleeding disorders, systemic bleeding, low platelet or neutrophil counts
- History of symptomatic non-traumatic intracranial hemorrhage or cerebral amyloid angiopathy
- Severe heart or lung diseases considered unsuitable for the study
- Women of childbearing potential who refuse contraception, pregnant or breastfeeding
- Currently participating in other drug or device trials
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Capital Medical University Affiliated Beijing Tiantan Hospital
Beijing, Beijing Municipality, China
Actively Recruiting
Research Team
Q
Qingyuan Liu, M.D.
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here